31 results about "Hypnotic agent" patented technology

The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.

The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.

The present invention provides novel pharmaceutical formulations of a substituted phenylacetic acid ester compound, which is useful as a short-acting sedative hypnotic agent for anesthesia and sedation. The pharmaceutical formulations are oil-in-water emulsions suitable for administration by injection. The invention further provides processes for the preparation of the formulation and the use of the formulation in medical treatment of a mammal.

The invention concerns the combination of a short-acting hypnotic agent and a compound of formula (I):Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The combination of this invention is useful in treating a variety of sleep disorders.

The invention relates to detection of anomalies related to a measurement of the hypnotic level of a subject. In order to detect when a measure indicative of the hypnotic level of a subject is anomalous either due to a medical reason or due to an interference, the measure is monitored and state information indicative of the activity of the autonomous nervous system of the subject and drug effect information indicative of the hypnotic drug effect in the subject are employed to check whether the measure fulfills a predetermined consistency condition requiring that the measure changes consistently with at least one of the drug effect information and the state information. An anomaly, indicative of an abnormal change in the measure, is detected when the measure fails to fulfill the predetermined consistency condition.

The invention relates to a kit for detecting an anxiolytic and hypnotic drug in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. 11 kinds of anxiolytic andhypnotic drugs can be detected at one time; target drugs and metabolites are monitored at the same time; the pretreatment process is simple, low in cost, high in sensitivity and high in specificity,separation and detection of the anxiolytic and hypnotic drugs are completed within 5 minutes, the accuracy and precision basically meet the requirements, the kit can be used for quantitative analysisof the anxiolytic and hypnotic drugs clinically, and a simple and rapid detection method is provided for monitoring the treatment concentration of the anxiolytic and hypnotic drugs in serum clinically.

The present invention provides novel compositions for the delivery of hypnotics across the oral mucosa. Specifically, the buffer system in the compositions of the present invention raises the pH of saliva to a pH of greater than about 7.8, thereby promoting substantially complete conversion of the hypnotic agent from its ionized form to its unionized form. As a result, doses of hypnotics are rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-individual variability. Additionally, delivery of hypnotics across the oral mucosa advantageously avoids hepatic first-pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. The invention also provides methods of treating sleep disorders such as insomnia using the compositions of the invention.

The present invention relates to an improved and industrially advantageous process for the preparation of N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula I, which is a key intermediate in the synthesis of zolpidem hemitartrate, a non-benzodiazepine hypnotic agent. The process includes reacting 3-(4-methyl)-benzoyl propionic acid of Formula IV, with alkyl chloroformate or pivaloyl chloride to get a mixed anhydride of Formula V; and reacting the mixed anhydride of Formula V with dimethylamine of Formula VI to get the N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula I.

The invention relates to a kit comprising a first container containing a chloral hydrate concentrate and a second container containing a diluent and application of the chloral hydrate concentrate andthe diluent to preparation of a medicament for use as a sedative-hypnotic agent.

The invention relates to an anesthesia analgesia drug composition. The drug composition comprises a compound drug composition which can serve as a sedative hypnotic drug and contains rRemimazolam, derivatives of rRemimazolam and a narcotics analgesic.

Polymorphs of N-methyl-N-(3-ä3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5- alpha Ü-pyrimidin-7-ylüphenyl)acetamide (Compound (1)), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II, is also provided.

The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.

The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a discontinuous phase in said matrix.

The invention discloses a 2-(2-chlorophenyl) quinazoline-4 (3H)-one derivative shown in formula (I) or pharmaceutically acceptable salts thereof. Compared with the existing first-line sedative and hypnotic drugs diazepam and midazolam, the compound has stronger drug effect and faster metabolism speed, can reduce the next-day residual effect, and is expected to be developed into a novel high-efficiency low-toxicity sedative and hypnotic drug.

The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions.

The present invention relates to a kit comprising a first container containing a chloral hydrate concentrate and a second container containing a diluent and the use of the chloral hydrate concentrate and the diluent in the preparation of a medicament for use as a sedative-hypnotic agent.